{"id":"W2546853358","doi":"10.1182/blood.v114.22.790.790","title":"Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Interim analysis; Cytarabine; Internal medicine; Randomization; Induction chemotherapy; Randomized controlled trial; Surgery; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003003884,0.0006361068,0.001901767,0.0008982347,0.0003098068,0.0001074593,0.0005624821,0.000408547,0.0005414991],"category_scores_gemma":[0.001653916,0.0004951697,0.000474187,0.000779476,0.000233518,0.0007040639,0.0000737041,0.0006022519,0.000007824808],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00201242,"about_ca_system_score_gemma":0.001253082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002902373,"about_ca_topic_score_gemma":0.0002151728,"domain_scores_codex":[0.9936453,0.001427184,0.00201348,0.00103103,0.001296272,0.0005867266],"domain_scores_gemma":[0.9936835,0.001880894,0.001232111,0.000788091,0.002137857,0.0002775165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8701676,0.004517875,0.000008985937,0.00001439831,0.002687865,0.000009730245,0.00482267,0.0001251261,0.07590333,0.00002943717,0.004766122,0.03694685],"study_design_scores_gemma":[0.8074058,0.1500873,0.0002950762,0.0001237464,0.0006078547,0.00002253458,0.001669005,0.0004318316,0.03653968,0.00002564093,0.002440032,0.0003515314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709262,0.00009750399,0.001596925,0.0008110896,0.001293113,0.01890598,0.005980935,0.0001343257,0.0002539247],"genre_scores_gemma":[0.9775851,0.0004887721,0.001393629,0.0002321404,0.000928373,0.001780424,0.01740499,0.00009056992,0.00009594939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1455694,"threshold_uncertainty_score":0.99975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03119918099127266,"score_gpt":0.3468058883991452,"score_spread":0.3156067074078726,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}